-
Inotiv partners with VUGENE for AI-driven drug discovery platform
-
Inotiv, Inc. (NOTV) Tops Q4 EPS by 8c, Beats on Revenue
-
Inotiv reports cybersecurity incident disrupting business operations
-
Inotiv, Inc. (NOTV) Misses Q3 EPS by 12c
-
Inotiv Inc. (NOTV) PT Raised to $2.50 at Jefferies
-
Inotiv, Inc. (NOTV) Tops Q2 EPS by 19c
-
Inotiv Inc. (NOTV) options active into the FDA reducing animal testing
-
Sea Pharmaceuticals Announces Strategic Relationship to Advance Treatments For Patients with CNS Disorders
-
Inotiv, Inc. (NOTV) Misses Q1 EPS by 22c, Misses on Revenue
-
Inotiv Inc. (NOTV) Announces Pricing of Public Offering of 6,000,000 Common Shares
-
Inotiv Inc. (NOTV) Launches Proposed Share Offering
-
Inotiv Inc. (NOTV) PT Raised to $6 at Lake Street Capital Markets
-
Inotiv, Inc. (NOTV) Tops Q4 EPS by 25c
-
Inotiv Inc. (NOTV) Files for 4.15M Share Offering by Selling Stockholders
-
Inotiv, Inc. (NOTV) Tops Q3 EPS by 184c
-
Inotiv Inc. (NOTV) Provides Business Updates

